NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NEI E-248-2012-0-PCT-02 Methods of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor PCT PCT PCT/US2013/068056 Expired
NEI E-248-2012-0-CA-04 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor CA National Stage 2890238 Abandoned
NEI E-248-2012-0-AU-03 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor AU National Stage 2013337702 Abandoned
NCI E-093-2013-1-US-01 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE US 61/899,061 Abandoned
NIDDK E-456-2013-2-PCT-01 Method of Increasing the Amount of Fetal Hemoglobin in a Cell and/or Mammal PCT PCT COMB PCT/US2013/067811 Expired
NIAID E-051-2002-0-US-08 METHOD FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION US CON 14/067,005 9415105 Expired PDF
NHLBI E-018-2014-0-US-01 Trans-Auricular Left Atrial Appendage Ligation US 61/896,048 Abandoned
NCI E-148-2011-0-US-09 ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER US National Stage 14/110,189 9266960 Issued PDF
NCI E-054-2013-2-EP-05 IL-15R ALPHA FORMS, CELLS EXPRESSING IL-15R ALPHA FORMS, AND THERAPEUTIC USES OF IL-15R ALPHA AND IL-15/IL-15R ALPHA COMPLEXES EP National Stage 13849581.7 Issued
NCI E-054-2013-2-AU-03 IL-15R ALPHA FORMS, CELLS EXPRESSING IL-15R ALPHA FORMS, AND THERAPEUTIC USES OF IL-15R ALPHA AND IL-15/IL-15R ALPHA COMPLEXES AU National Stage 2013334610 Issued
NCI E-054-2013-2-JP-07 IL-15R ALPHA FORMS, CELLS EXPRESSING IL-15R ALPHA FORMS, AND THERAPEUTIC USES OF IL-15R ALPHA AND IL-15/IL-15R ALPHA COMPLEXES JP National Stage 2015-539758 Issued
NCI E-054-2013-2-PCT-01 IL-15R ALPHA FORMS, CELLS EXPRESSING IL-15R ALPHA FORMS, AND THERAPEUTIC USES OF IL-15R ALPHA AND IL-15/IL-15R ALPHA COMPLEXES PCT PCT COMB PCT/US2013/066424 Expired
NIAID E-449-2013-0-US-01 Small Molecule Imaging Of Fungi By Positron Emission Tomography Scanning US 61/894,754 Abandoned
NCI E-520-2013-0-US-01 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein US 61/894,482 Abandoned
NCI E-019-2014-0-US-01 COMPOUNDS THAT BIND TO HIV-1 REV RESPONSE ELEMENTT US 61/894,849 Abandoned
NIA E-008-2011-0-US-07 Identification Of Stem/Progenitor Cells In Adult Human Pancreas US National Stage 13/981,891 10273458 Issued PDF
NIAID E-263-2005-0-US-07 TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERSMIDIS AND RELATED INFECTIONS US DIV 14/058,610 8921071 Issued PDF
NCI E-144-2011-0-US-03 Use of Pyruvate or Succinate to Enhance the Efficacy of a Hypoxia Activated Prodrug for the Treatment of Tumors US National Stage 14/112,906 9402820 Issued PDF
NHLBI E-183-2004-1-US-08 Compositions and Methods for Treating Hyperproliferative Disorders US CON 14/058,000 Abandoned
NCI E-002-2014-0-US-01 Human Monoclonal Antibodies Against The Middle East Respiratory Syndrome CoronaVirus (MERS-CoV) And Engineered Bispecific Fusions With Inhibitory Peptides US 61/892,750 Abandoned
NCI E-001-2014-0-US-01 ANTIBODIES THAT SPECIFICALLY BIND ATAXIA TELANGIECTASIA-MUTATED AND RAD3-RELATED KINASE PHOSPHORYLATED AT POSITION 1989 AND THEIR USE US 61/893,070 Abandoned
NCATS E-010-2013-0-CA-03 Sensor And Device For Real Time Detection Of Plasma Metabolites CA National Stage 2888743 Issued
NCI E-272-2012-0-PCT-02 Compositions and Methods for Enhancing Cancer Immunotherapy PCT PCT PCT/US2013/065452 Expired
NCATS E-010-2013-0-PCT-02 Sensor And Device For Real Time Detection Of Plasma Metabolites PCT PCT PCT/US2013/065548 Expired
NEI E-099-2010-0-US-06 Methods of Treating Age-Related Macular Degeneration US National Stage 13/977,946 Abandoned
NCI E-056-2011-0-NZ-14 YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS NZ National Stage 616696 Issued
NCI E-130-2011-0-US-05 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF US National Stage 14/111,860 9206257 Issued PDF
NHLBI E-759-2013-0-US-01 Vascular Dilators US 61/890,961 Abandoned
NCI E-024-2009-0-FR-12 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS FR EP 13188475.1 Issued
NCI E-024-2009-0-DE-11 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS DE EP 13188475.1 Issued
NCI E-024-2009-0-GB-13 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS GB EP 13188475.1 Issued
NIDDK E-743-2013-0-US-01 THERAPEUTIC POLYPEPTIDES AND THEIR USE US 61/890,585 Abandoned
NCI E-181-2009-4-US-06 Peptide Mimetic Ligands Of Polo-like Kinase 1 Polo Box Domain and Methods of Use US National Stage 14/111,540 10266565 Issued PDF
NINDS E-251-2005-2-JP-07 Improvements To Vibro-tactile Stimulation Device JP DIV 2013-213610 Issued
NCI E-068-2011-0-US-03 Human Monoclonal Antibodies That Bind Insulin-Like Growth Factor (IGF) I And II US ORD 14/111,507 9150644 Issued PDF
NCI E-181-2009-4-JP-05 Peptide Mimetic Ligands of Polo-like Kinase1 Polo Box Domain and Method of Use JP National Stage 2014-505275 Abandoned
NCI E-344-2013-0-US-01 TEM8 ANTIBODIES AND THEIR USE US 61/889,958 Abandoned
NIAID E-531-2013-0-US-01 NOVEL EPSTEIN-BARR VIRUS VACCINES US 61/889,840 Abandoned
NHLBI E-241-2010-0-KR-12 Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery KR National Stage 10-2013-7026982 Abandoned
NCATS E-757-2013-0-US-01 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives As Potent And Selective Inhibitors Of Human 12-Lipoxygenase. US 61/889,396 Abandoned
NIDCR E-736-2013-0-US-01 Detection of Hepatitis Delta Virus and Use Thereof For The Diagnosis and Treatment of Sojgren's Syndrome US 61/888,706 Abandoned
NHLBI E-261-2012-0-US-02 Imaging Methods and Computer-Readable Media US ORD 14/049,096 9449377 Issued PDF
NEI E-075-2011-0-US-06 Methods of Diagnosing and Treating Age-Related Macular Degeneration US National Stage 13/981,368 Abandoned
NICHD E-157-2011-0-US-04 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders And Methods Of Using The Same US National Stage 14/110,393 9629816 Issued PDF
NCATS E-217-2013-0-PCT-02 A new chemical entity useful for treating various diseases PCT PCT PCT/US2013/063610 Expired
NCI E-771-2013-0-US-01 Modified Pseudomonas Exotoxin A US 61/887,418 Abandoned
NIAID E-089-2012-0-PCT-02 A Formulation Of Mycobacterial Components As An Adjuvant For Inducing TH17 Response PCT PCT PCT/US2013/063388 Expired
NCI E-148-2011-0-JP-08 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer JP National Stage 2014-503673 Issued
NCI E-141-2008-0-NZ-13 Complexes Of IL-15 And IL-15R AIpha And Uses Thereof NZ DIV 616254 Issued
NCI E-148-2011-0-IL-07 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer IL National Stage 228686 Issued